U.S. FDA approvals had a modest increase during the first four months of 2023 compared to last year, but still fall short of the peaks seen in 2019 and 2021.

Biopharma deals April 2023

Fewer biopharma deals raise similar value year-over-year, while M&A value declines

May 23, 2023

By Amanda Lanier

No Comments

Biopharma has experienced relatively stable deal value year-over-year, despite a 24% decline in the number of deals through April. M&As, however, have brought in the lowest amount in years.

Med-tech gainers and losers for May 15-19, 2023

May 22, 2023

No Comments

The top 10 med-tech stock gainers and losers for the week.

Biggest gainers and losers for May 15-19, 2023

May 22, 2023

No Comments

The top 10 biopharma stock gainers and losers for the week.

Med-tech deals April 2023

Med-tech deals surge to highest value in years as M&As slow down

May 19, 2023

By Amanda Lanier

No Comments

Med-tech has seen significant deal value growth during the first four months of 2023, despite a decline in the number of deals. In contrast, the value of mergers and acquisitions has experienced a notable downturn.

Biopharma money raised: Jan. 1-May 18, 2023

May 19, 2023

No Comments

Year-to-date money raised in public, private and other financings of biopharma companies.

Money raised by biopharma

May 19, 2023

No Comments

Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.

Today's news in brief
BioWorld
BioWorld briefs for Nov. 25, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 25, 2024.
J&J’s Ottava robotic system approved for US pivotal trial
BioWorld MedTech
Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...
‘Evo’ AI can design complete genomes
BioWorld Science
The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...
Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection
BioWorld Asia
Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Analysis and data insight RSS

Analysis and data insight
RSS